Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

Completed

• Conditions: Meningioma of Brain

• Registration Number: NCT06614205
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Detailed Description

Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.

Study Timeline

• Study First Submitted: 2024-06-06
• Study First Submitted QC: 2024-09-24
• Study First Posted: 2024-09-26
• Study Start: 2024-11-01
• Primary Completion: 2025-01-01
• Status Verified: 2025-02
• Study Completion: 2025-02-25
• Last Update Submitted: 2025-02-28
• Last Update Posted: 2025-03-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• patients treated for menigioma at nancy hospital
• patients who performed 3 scintigraphics exams during there treatment

Exclusion Criteria

• patients deprived of liberty
• patient who refused to collect data retrospectively

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnostic accuracy for progression free survival	Day 1	Accuracy of tumor dosimetry to predict 6-month progression-free survival.

Secondary Outcome Measures

Name	Time	Method
Diagnostic accuracy for overal survival	Day 1	Accuracy of tumoral dosimetry in predicting 6-month overall survival

Trial Locations

Locations (2)

CHRU de NANCY; 🇫🇷 Vandoeuvre les Nancy cedex, France

Nuclear medicine Department CHRU de NANCY; 🇫🇷 Vandoeuvre les Nancy cedex, France